This study used genetic mutation models to interrogate the role of the ETS variant (ETV) family of transcription factors in renal cyst biology. Nephron-specific deletion of ETV4 and ETV5 produced de novo cyst formation, indicating that these transcription factors restrain the earliest phase of cyst development in the kidney. The authors emphasize that cyst formation can be separated conceptually into two phases: initiation, the appearance of new cysts, and progression/promotion, the subsequent growth and expansion of those cysts into a pathogenic state.
Although deletion of ETV4 and ETV5 was sufficient to trigger initial cysts, the majority of those early cysts did not continue to expand as animals matured. Only a limited number of initiated cysts underwent further growth in the absence of additional genetic changes. These observations support a model in which loss of ETV4/ETV5 removes restraints on initiation but is not by itself a robust driver of sustained cyst expansion.
The investigators extended the genetic approach by including ETV1. Additional deletion of ETV1 on top of ETV4/ETV5 loss changed the cyst trajectory: combined loss of ETV1, ETV4, and ETV5 was required for continuous initiation of new cysts during growth and also promoted further cyst expansion. In other words, while ETV4/ETV5 loss initiates cyst formation, elimination of ETV1 appears necessary to shift the process toward ongoing initiation and enhanced promotion/growth of cysts.
This hierarchical requirement suggests functional redundancy or cooperative roles among ETV family members in maintaining normal nephron architecture and preventing transition to pathogenic cystic disease. The data indicate that disrupting multiple ETV factors moves the system from sporadic initiation toward sustained pathogenic cystogenesis.
To assess signaling pathways that modulate the growth phase, the authors used a pharmacologic inhibitor of the hedgehog pathway, cyclopamine. Administration of cyclopamine attenuated the promotion of cyst progression but had little measurable effect on cyst initiation. This dissociation suggests that hedgehog pathway activity is more important for the growth and enlargement of existing cysts than for the initial formation of cysts.
The finding that a hedgehog inhibitor limits progression but not initiation reinforces the concept that molecular drivers of initiation and progression can be distinct and selectively targetable. Cyclopamine’s effect on promotion implies hedgehog signaling contributes to the pathogenic transition and could be a therapeutic entry point to slow or limit cyst growth once initiation has occurred.
Taken together, the genetic deletion experiments targeting ETV1, ETV4, and ETV5 and the pharmacologic hedgehog inhibition work support a model in which cyst initiation and cyst progression are genetically and molecularly distinct processes. Initial cyst formation can be precipitated by loss of specific transcriptional regulators (ETV4/ETV5), but sustained initiation and enhanced growth require broader disruption including ETV1. Conversely, progression of already-initiated cysts can be mitigated by blocking the hedgehog pathway.
This dichotomy clarifies how pathogenic cysts may arise through repeated or continuous initiation followed by promotion into larger, clinically significant lesions. The separation also opens the possibility of phase-specific interventions: targeting transcriptional regulators or upstream triggers to prevent initiation, and modulating signaling pathways such as hedgehog to limit progression.
The study provides preclinical evidence that initiation and progression of renal cysts can be differentially modulated: genetic loss of ETV family factors favors initiation and, when extended to include ETV1, promotes continuous cystogenesis, while hedgehog inhibition with cyclopamine impairs progression. These findings suggest two potential translational approaches—preventing initiation by maintaining ETV-mediated transcriptional control or limiting growth by inhibiting progression-promoting signaling pathways.
The report is a bioRxiv preprint posted August 26, 2026, by Borum Ryu, Ligyeom Ha, Del L Dsouza, Erika I Boesen, and Sung-Ho Huh. The authors declared no competing interests. Details such as experimental timelines, quantitative outcomes, specific animal models, dosing regimens, and histological metrics were not reported in the source abstract and would require consultation of the full manuscript for operational or clinical translation.